Affymax (AFFY) Shares Surge as FDA Says Peginesatide Works as Well as Amgen Products
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Shares of Affymax (Nasdaq: AFFY) are rallying in pre-market trade Monday morning following news out of the FDA the company's anemia drug peginesatide works as well as Amgen's (Nasdaq: AMGN) epogen, aranesp.
The FDA note comes ahead of a December 7th advisory panel review of the product.
Affymax shares last traded at $6.53, up more than 24 percent from Friday's close.
The FDA note comes ahead of a December 7th advisory panel review of the product.
Affymax shares last traded at $6.53, up more than 24 percent from Friday's close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
